A deeper look into the TRILUMINATE pivotal trial results shows that transcatheter edge-to-edge repair (TEER) for patients with symptomatic, severe tricuspid regurgitation resulted in meaningfully improved quality of life in patients with mostly concomitant, but treated, left-sided valve disease.